Table 1 Baseline characteristics of all randomised patients.
| Characteristic | Placebo | Daclizumab 1 mg/kg | Daclizumab 2 mg/kg | p Value |
|---|---|---|---|---|
| No of patients | 56 | 56 | 47 | |
| Male sex (n (%)) | 33 (58.9) | 29 (51.8) | 25 (53.2) | 0.778 |
| White race (n (%)) | 47 (83.9) | 45 (80.4) | 38 (80.9) | 0.902 |
| Age (y) (mean (SD)) | 40.7 (13.23) | 47.4 (14.09) | 42.6 (15.37) | 0.041 |
| Body weight (kg) (mean (SD)) | 80.5 (19.24) | 76.6 (19.45) | 79.8 (19.29) | 0.536 |
| Disease duration (y) (mean (SD)) | 6.8 (7.35) | 7.8 (6.62) | 8.3 (8.06) | 0.563 |
| Involved colonic area (n (%)) | ||||
| Left sided | 46 (82.1) | 46 (82.1) | 33 (70.2) | 0.411 |
| Extensive | 10 (17.9) | 10 (17.9) | 13 (27.7) | |
| Mayo clinic score (mean (SD)) | 8.0 (1.66) | 7.8 (1.61) | 8.0 (1.74) | 0.735 |
| Concomitant medication (n (%)) | ||||
| Corticosteroids | 19 (33.9) | 21 (37.5) | 17 (36.3) | 0.936 |
| Azathioprine/6‐MP | 12 (21.4) | 12 (21.4) | 9 (19.1) | 0.966 |
| Current smoker (n (%)) | 6 (10.7) | 3 (5.4) | 4 (8.5) | 0.589 |
6‐MP, 6‐mercaptopurine.